Clik here to view.
鞍石生物在2023年AACR年会上公布PLB1004在治疗EGFR突变非小细胞肺癌患者方面的中期数据结果
北京 (美国商业资讯)–鞍石生物科技（下称“鞍石生物”或“公司”）今天公布了PLB1004一期研究的中期结果。这家专注于精准肿瘤治疗的临床阶段生物科技公司目前正在开展PLB1004一期研究，这些中期数据是今天（CT102）在美国佛罗里达州奥兰多举行的2023年美国癌症研究协会（AACR）年会上公布的。...
View ArticleClik here to view.
Orum Therapeutics Unveils New Program at AACR 2023, Highlighting Cbl-b...
BOSTON & DAEJEON, South Korea Orum Therapeutics, a clinical-stage private biotechnology company pioneering cell-specific targeted protein degradation (TPD² ™) and targeted protein stabilization...
View ArticleClik here to view.
InnoCare Announces Orelabrutinib Becomes the First and the Only BTK Inhibitor...
BEIJING InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company, announced today that its BTK inhibitor orelabrutinib received approval from the China National Medical...
View ArticleClik here to view.
AACR 2023で発表されたデータは、エクセンシアの臨床および前臨床開発に注目
OXFORD, England （ビジネスワイヤ） — エクセンシア（Nasdaq: EXAI）は本日、2023年4月14～19日にフロリダ州オーランドのオレンジ・カウンティー・コンベンション・センターで開催される2023年米国がん学会（AACR）年次総会で4件の発表を行いました。...
View ArticleClik here to view.
2023年AACR大会公布的数据凸显了Exscientia在临床和临床前方面的发展
英国牛津 (美国商业资讯)–Exscientia plc (Nasdaq: EXAI)今天公布了在2023年美国癌症研究学会(AACR)年度会议上展示的四项成果，这场会议于2023年4月14日至19日在佛罗里达州奥兰多举行。 Exscientia创始人兼首席执行官Andrew...
View ArticleClik here to view.
BeiGene Announces Positive Phase 3 Tislelizumab Trial in Advanced Gastric or...
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the global RATIONALE 305 trial met its...
View ArticleClik here to view.
Quizartinib NDA Review for Patients with Newly Diagnosed FLT3-ITD Positive...
TOKYO & BASKING RIDGE, N.J. Daiichi Sankyo (TSE: 4568) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) of...
View ArticleClik here to view.
PharmaEssentia Corporation Announces Closing of Global Depositary Receipt...
TAIPEI, Taiwan PharmaEssentia Corporation (TPEx:6446, LuxSE: PHECA, PHECR), a leading fully integrated biopharmaceutical company in Taiwan, today announced the closing of its Global Depositary...
View ArticleClik here to view.
Albatroz Therapeutics Secures $3 Million to Develop First-Ever Therapy...
SINGAPORE Albatroz Therapeutics, a biotechnology company targeting tissue remodeling to stop cancer growth and treat arthritis, today announced it has secured $3 million USD in funding led by Outram...
View ArticleClik here to view.
BeiGene Announces Goals Focused on Sustainable Growth and Workforce Diversity...
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, announced several new Environmental, Social, and Governance...
View ArticleClik here to view.
BeiGene to Highlight Broad Oncology Portfolio at the 2023 ASCO Annual Meeting
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, will present data from its broad solid tumor and hematology...
View ArticleClik here to view.
Alentis Therapeutics 宣布 ALE.F02 靶向 Claudin-1 多次剂量递增一期研究取得积极成果
巴塞尔，瑞士 (美国商业资讯)–今日，Alentis Therapeutics (“Alentis”) 宣布了 ALE.F02 靶向 Claudin-1(CLDN1) 的首次人体一期临床研究在多次剂量递增 (MAD) 阶段取得的进展。作为一家临床阶段生物科技公司，Alentis 致力于针对器官纤维化和 CLDN1+ 肿瘤研发突破性治疗方案。 该试验招募了 24 名受试者：其中 18...
View ArticleClik here to view.
Clinical Study Result of Orelabrutinib in Patients with R/R MCL Published by...
BEIJING Blood Advances, part of leading hematology journal Blood, also a Journal of the American Society of Hematology, recently published the clinical study result of BTK (Bruton Tyrosine Kinase)...
View ArticleClik here to view.
EdiGene to Unveil Promising Preclinical POC Data for LEAPER™ 2.0-based in...
BEIJING EdiGene, Inc., a clinical-stage biotechnology company focused on developing transformative gene-editing therapies, announced an oral presentation on the preclinical proof-of-concept (POC)...
View ArticleClik here to view.
CANbridge-UMass Chan Medical School Spinal Muscular Atrophy Gene Therapy...
BURLINGTON, Mass. & BEIJING CANbridge Pharmaceuticals Inc. (HKEX:1228), a leading China-based global biopharmaceutical company committed to the research, development and commercialization of...
View ArticleClik here to view.
SOPHiA GENETICS’ SOPHiA DDM™ HRD Solution is Tapped by Unipath Specialty...
BOSTON & LAUSANNE, Switzerland SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced that Unipath...
View ArticleClik here to view.
PharmaEssentia Initiates Phase 3b Trial of Ropeginterferon alfa-2b-njft...
BURLINGTON, Mass. PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TPEx:6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven...
View ArticleClik here to view.
Datamatics Partners with Alkermes to Help Support Patients
LIVONIA, Mich. Datamatics, a global Digital Technologies, Operations and Experiences Company, has entered into a strategic partnership with Alkermes, a global biopharmaceutical company developing...
View ArticleClik here to view.
Exscientia任命哈佛教授Franziska Michor博士为董事会成员
英国牛津 (美国商业资讯)– Exscientia plc (Nasdaq: EXAI)今天宣布任命教授Franziska Michor博士为公司董事会成员。Michor是一名计算生物学教授，任职于Dana-Farber Cancer Institute数据科学部门、哈佛大学T.H. Chan公共卫生学院生物统计系和哈佛大学干细胞与再生生物学系。董事会目前由七名董事组成。...
View ArticleClik here to view.
エクセンシアがハーバード大学のフランツィスカ・ミチャー教授を取締役に任命
英オックスフォード （ビジネスワイヤ） — エクセンシア（Nasdaq: EXAI）は、本日、フランツィスカ・ミチャー教授を取締役に任命したと発表しました。フランツィスカ・ミチャーは、ダナ・ファーバーがん研究所のデータサイエンス学部、ハーバード公衆衛生大学院の生物統計学部、ハーバード大学幹細胞・再生生物学部門で計算生物学の教授をつとめています。現在、取締役会は7名で構成されています。...
View Article